Louisville, KY (November 20, 2012)

Reporting on the recent Clinical Trials on Alzheimer’s Disease (CTAD) conference held in Monte Carlo, Alzheimer’s Research Forum (www.alzforum.org) reported a pressing need for biomarkers as outcome measures in Alzheimer’s drug trials, and a heightened interest in electroencephalography (EEG) and event-related potentials (ERPs). The story, CTAD: EEG Gains Luster as More Trials Incorporate Biomarkers, noted that event-related potentials directly measure the brain’s electrical, or synaptic, activity and provide a direct, physiological measure of cognitive function, i.e., a cognitive biomarker.

Several Alzheimer’s thought leaders stated that ERPs can be useful both in cognitive assessments and in evaluating the pro-cognitive effects of novel therapies. “Given the recent challenges in Alzheimer’s disease therapeutic trials, we are hopeful that the COGNISION™ System will play an important and valuable role in the drug development process for new therapies targeting Alzheimer’s disease and other neurological disorders” said K.C. Fadem, President of Neuronetrix. Neuronetrix is developer of the COGNISION™ System, a proprietary ERP and qEEG (quantitative EEG) device which can be used by clinical and academic researchers in investigations of many neurological disorders and cognitive processes.

The COGNISION™ System includes a user-friendly device to record electroencephalographic (EEG) data and an online database to store subject information. The system combines many useful and unique features, which are detailed in the COGNISION™ Product Brochure. Upon approval by the FDA, COGNISION™ will be used by clinicians for the evaluation of Alzheimer’s disease and other neurological disorders which impact cognitive function.